Our quantitative label-free LC-MS/MS approach identified two proteins (C4BPA and CLU) in higher abundance in the plasma collected before any therapy from patients whose HL subsequently relapsed: this makes them candidate early biomarkers of the risk of relapse. This evidence concerns the gene CLU and Hodgkins lymphoma.